MO01.14 Real-World Effectiveness and Safety of Afatinib Following Immunotherapy (IO) in the Treatment of Metastatic, Squamous Cell/Mixed Histology Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Trial in the US
J. Subramanian , A. Cseh , E.S. Kim , W. Tang
Journal of Thoracic Oncology 16 ( 1)
2021
MO01.41 Using an Exploratory Composite Endpoint to Evaluate the Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer
J. Jaal , R.K. Malik , D. Radosavljevic , J. Subramanian
Journal of Thoracic Oncology 16 ( 1)
1
2021
P60.10 Tumor Neoantigen Burden and Immune Environment in Driver Alteration-Positive Lung Adenocarcinoma.
L. Kujtan , A. Masood , J. Subramanian , A.K. Ganti
Journal of Thoracic Oncology 16 ( 3)
2021
135P The real-world use of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor mutated (EGFRm) advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC) patients
N. Navani , J. Gregg , N. Leighl , R. Hui
Journal of Thoracic Oncology 16 ( 4)
2021
143P Physician perceptions of barriers to epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC)
N. Navani , J. Gregg , N. Leighl , R. Hui
Journal of Thoracic Oncology 16 ( 4)
2021
144P Delays in epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/ IIIc/ IV) non-small cell lung cancer (NSCLC) patients and their impact on the use of first line tyrosine kinase inhibitor (TKIs) in a real-world setting
N. Navani , J. Gregg , N. Leighl , R. Hui
Journal of Thoracic Oncology 16 ( 4)
2021
Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) analysis
J. Subramanian , V. Vamsidhar , B. W. Goodgame , R. Govindan
Journal of Clinical Oncology 26 ( 15_suppl) 22106 -22106
2
2008
Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
D. Morgensztern , W.-T. Lim , J. Subramanian , A. Viswanathan
Journal of Clinical Oncology 23 ( 16_suppl) 7298 -7298
4
2005
Outcomes of resected stage 1 non-small cell lung cancer (NSCLC) in patients (Pts) aged 70 years and older
A. K. Viswanathan , B. Goodgame , W. T. Lim , F. Gao
Journal of Clinical Oncology 23 8027 -8027
2005
PCN48 ECONOMIC BURDEN ASSOCIATED WITH SEVERE ADVERSE EVENTS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH FIRST-LINE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS
D. Lejeune , M. Pavilack , M. Dersarkissian , A. Fernandes
Value in Health 22
2019
1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
J. Subramanian , V. Moreno , J. Bosch-Barrera , J. Pikiel
Annals of Oncology 31
1
2020
1402P Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting
J. Subramanian , J. Gregg , H. Wang , P. Sun
Annals of Oncology 31
2020
Lung cancer in never-smokers: A single institutional experience
J. Subramanian , F. Gao , N. Sainani , A. K. Viswanathan
Journal of Clinical Oncology 24 ( 18_suppl) 17044 -17044
2006
P2.01-60 Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients
L. Kujtan , C.R. Vibat , V. Singh , K. Kennedy
Journal of Thoracic Oncology 13 ( 10)
2018
P2.15-26 Rates and Economic Burden of Adverse Events in Patients With Metastatic NSCLC Treated with EGFR-TKIs
J. Subramanian , F. Laliberté , A. Fernandes , M. Pavilack
Journal of Thoracic Oncology 13 ( 10)
2018
MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs
A. Chiang , A. Fernandes , M. Pavilack , J. Wu
Journal of Thoracic Oncology 13 ( 10)
8
2018
Pulmonary neuroendocrine carcinomas: A population-based survey
D. Morgensztern , J. Subramanian , R. Govindan
Journal of Clinical Oncology 26 17522 -17522
2008
Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
D. Adkins , J. Ley , B. Nussenbaum , J. Diaz
Journal of Clinical Oncology 29 5560 -5560
6
2011
Real-world utilization of targeted therapy in cancer treatment.
J. Subramanian , A. Vlahiotis , S. Frazee , K. Snider
Journal of Clinical Oncology 29
1
2011
A survey on insomnia in patients with non-small cell lung cancer (NSCLC).
J. Subramanian , M. Q. Baggstrom , E. Gilstrap , T. De Shields
Journal of Clinical Oncology 28
2010